Author: admin

E-Heart Care, NHU’s Program to Elevate Employee Well-Being

In today’s fast-paced society, work stress, life challenges, and physical exhaustion are triggering a silent “burnout crisis” among modern professionals.

To prioritize employee well-being, professional growth, and life satisfaction—while enhancing psychological resilience, relieving work stress, and fostering emotional connection—NHU launched the E-Heart Care program on February 28. The 24-hour mental health support hotline was also activated, marking a big advancement in our employee care system.

This program has received strong backing from relevant institutions and departments. From the top-level design and system development to its execution, it has been carefully guided to ensure it is well structured and implemented.

At the launch event, Mr. Hu Baishan, Vice Chairman and President of NHU, emphasized the importance of employee care from societal and corporate perspectives. He noted that prioritizing staff well-being aligns with social responsibility, corporate culture, and long-term growth. He called for a structured care system shaped by leadership emphasis, policy refinement, managerial engagement, and innovative approaches, urging all employees and managers to collaborate in fostering a harmonious and dynamic workplace for a better future.

Mental health expert Professor Wang Guoqiang gave a lecture on the role of EAP (Employee Assistance Programs) on corporate development, addressing workplace stress and common mental challenges. Drawing on his experience and expertise, he shared practical strategies for self-care and effective communication, offering actionable insights for managers to enhance team performance and optimize leadership. His lecture was rich in practical knowledge, offering valuable takeaways for the attendees.

Supported by a team of experts, the event featured interactive sessions: one-on-one counseling, stress-relief brainwave analysis, OH card self-exploration, TCM auricular acupuncture, and health consultations. These services—praised for their professionalism and personalized care—helped participants reconnect with themselves, process emotions, relieve stress, and recharge.

Employee well-being and growth are critical to corporate success. NHU has long prioritized the value of talents, fostering a “mentorship culture” and a supportive workplace through initiatives like employee interviews, health checkups, mental wellness workshops, hardship assistance, and diverse team-building activities. Complementing these efforts, NHU also champions a culture of continuous learning via rotation systems, knowledge-sharing platforms, and mentorship-coaching frameworks. This ensures holistic support for employees’ careers and well-being, enhancing their sense of belong and security while strengthening team cohesion and driving steady and sustainable corporate progress.

Media Contact
Company Name: Lingrong Culture
Contact Person: Wang Yurong
Email: Send Email
Phone: 2134007851
Address:3185 Wilshire blvd
City: Los Angeles
State: CA
Country: United States
Website: www.lingrongculture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: E-Heart Care, NHU’s Program to Elevate Employee Well-Being

EBike Market Size, Share, Industry Trends & Forecast 2024-2030

“EBike Market – Global Forecast to 2030”
EBike Market by Class (Class I, II, & III), Battery (Li-ion, Li-ion Polymer, Lead Acid), Motor (Mid, Hub), Mode (Throttle, Pedal Assist), Usage (Mountain/Trekking, City/Urban, Cargo), Speed, Battery Capacity, Component, & Region – Global Forecast to 2030

The global e-bike market is projected to grow from USD 48.72 billion in 2024 to USD 71.48 billion by 2030 at a CAGR of 6.6%. The worldwide demand for e-bikes is growing rapidly as customers see them as an eco-friendly solution for commutes, with rising fuel prices supporting this inclination. Government bodies in various cities worldwide have undertaken initiatives to build bicycle highway lanes for e-bikes.

European e-bike sales declined in 2023 due to wars, inflations, overstocks of e-bike components, and a global economic slowdown. Furthermore, due to wars, European consumers do not want to spend more money buying e-bikes. According to data from the European Cycling Industry Federation (ECF), European e-bike sales declined by 15.3% in 2023. This is a significant drop from the 11.2% growth the market saw in 2022. In 2024, the e-bike market saw a decline of 3.1% and is expected to increase from 2025 due to the growing popularity of e-bikes for commuting and leisure; governments worldwide are investing in infrastructure and incentives to promote e-bike use. An increase in demand for micro-mobility service providers, a rise in sales of e-bikes, and a rise in demand for energy-efficient e-bikes are some of the factors expected to increase the demand for >2 kg –

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=110827400

Lithium-ion in the battery segment is forecasted to be the largest e-bike market.

Ebikes equipped with lithium-ion batteries are projected to hold the largest market share, attributed to the numerous advantages these batteries offer, including superior lifecycle, high energy density, wide operating temperatures, and a higher power-to-weight ratio compared to other battery types. Lithium-ion batteries have become the preferred choice for electric bikes over lead-acid batteries due to their superior performance and long-term benefits. One of the critical advantages of lithium-ion batteries is their higher energy density, which allows them to store more energy in a smaller and lighter package compared to lead-acid batteries. This translates to more extended range and reduced overall vehicle weight, making lithium-ion batteries ideal for electric bikes. Another significant advantage of lithium-ion batteries is their longer lifespan. They can handle more charge cycles than lead-acid batteries, with lithium-ion batteries lasting 2000-5000 charge cycles, while lead-acid batteries have a shorter lifespan. Lithium-ion batteries require less frequent replacement, making them a more cost-effective option in the long run. Furthermore, the prices of lithium-ion batteries have witnessed a significant decline in recent years, plummeting by approximately 90%. Intensifying competition within the market has compelled manufacturers to slash costs to maintain competitiveness.

Mid Motor is forecasted to be the fastest-growing e-bike market in the motor segment.

The mid-drive motor is forecasted to be the fastest-growing segment in the bike market. Mid-drive motors are positioned near the pedals, where a traditional bike’s crankset is. This placement allows them to engage the drivetrain directly, resulting in a more natural and responsive riding experience than hub motors on the wheels. Mid-drive motors can be more powerful than hub motors, offering excellent assistance when climbing hills or accelerating. Additionally, they deliver higher torque, which translates to better pulling power, which is especially beneficial for tackling challenging terrain or carrying heavy loads. Mid-drive motors suit various e-bikes, including mountain, commuter, and gravel. Mid motors manage batteries efficiently while consistently delivering power. North America and Europe shifted towards mid-motor motors compared to hub motors because mid-drive motors place the weight near the center of the bike, which can improve handling and balance compared to hub motors concentrated in the wheels. This is a significant advantage for performance-oriented riders and those tackling technical terrain, and these regions are facing high demand for mountain/trekking bikes. Europe has the largest market for mountain/trekking e-bikes, with a market share of 63% in value. Meanwhile, mountain/trekking e-bikes are North America’s second-fastest-growing e-bike type after cargo e-bikes.

North America region holds the largest share of the EBike Market.

In North America, cargo e-bikes are expected to grow at the highest CAGR due to the increased adoption of electric bikes for transporting goods from one place to another, traffic congestion, and rising fuel prices in North American cities. Cargo e-bikes offer a faster and greener alternative to traditional delivery vans or trucks, especially for last-mile deliveries. Ebikes require minimal maintenance and have lower electricity costs compared to gas-powered vehicles. Some regions offer subsidies or tax breaks for businesses switching to e-bikes, further boosting their adoption. This is increasing the demand for cargo e-bikes. In December 2024, AIMA EBIKE USA and its North American dealer team announced their entry into North America at CES 2024. AIMA launched models like the Big Sur and Santa Monica, featuring Bafang’s H550 and H560 systems, which gained strong interest.

Major players operating in the Asia Oceania e-bike market are Giant Manufacturing Co. Ltd (Taiwan), Hero Lectro (India), TAV Systems (Australia), Yamaha Motor Company (Japan), Merida Industry Co. (Taiwan), and Emotorad (India)

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=110827400

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/electric-bike-market-110827400.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EBike Market Size, Share, Industry Trends & Forecast 2024-2030

Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in the competitive pharmaceutical landscape with in-depth Pipeline Insights! Discover the latest advancements, key Merkel Cell Carcinoma Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report

Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report

  • In February 2025:- H. Lee Moffitt Cancer Center and Research Institute– The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will stimulate the body’s immune system to work against tumor cells. This study will test an investigational use of nivolumab.
  • In February 2025:- Sensei Biotherapeutics Inc.;- Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
  • DelveInsight’s Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
  • The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.

Uncover Merkel Cell Carcinoma groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Merkel Cell Carcinoma Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Merkel Cell Carcinoma Clinical Trials Assessment

Merkel Cell Carcinoma Emerging Drugs Profile

  • Domatinostat: 4SC

Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).

  • Cavrotolimod: Exicure

Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.

The Merkel Cell Carcinoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
  • Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.

Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! From early-stage research to late-phase Merkel Cell Carcinoma Clinical Trials, our analysis covers key Merkel Cell Carcinoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Merkel Cell Carcinoma Treatment Drugs

Merkel Cell Carcinoma Companies

ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.

Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The future of medicine is evolving rapidly! Get detailed insights into ongoing Merkel Cell Carcinoma Clinical Trials, major Companies driving innovation, and the most anticipated Emerging Drugs in the pipeline. Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
  • Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Merkel Cell Carcinoma Emerging Drugs are set to revolutionize treatment landscapes? Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Find answers in our latest Merkel Cell Carcinoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Merkel Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mid Stage Products (Phase II)
  7. Domatinostat: 4SC
  8. Drug profiles in the detailed report…..
  9. Early Stage Products (Phase I/II)
  10. XmAb18087: Xencor
  11. Drug profiles in the detailed report…..
  12. Preclinical stage products
  13. SNS-401-NG: Sensei Biotherapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Merkel Cell Carcinoma Key Companies
  17. Merkel Cell Carcinoma Key Products
  18. Merkel Cell Carcinoma- Unmet Needs
  19. Merkel Cell Carcinoma- Market Drivers and Barriers
  20. Merkel Cell Carcinoma- Future Perspectives and Conclusion
  21. Merkel Cell Carcinoma Analyst Views
  22. Merkel Cell Carcinoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Chris “Kirbopher” Niosi Focuses on Growth and Future Projects in Animation and Voice Acting

LOS ANGELES, CA, UNITED STATES – Veteran voice actor and animator Chris “Kirbopher” Niosi, widely recognized for his contributions to anime and video games, is reaffirming his commitment to personal and professional growth as he looks ahead to new projects in 2025.

With over a decade in the industry, Niosi has lent his voice to major titles such as Mob Psycho 100, Hunter x Hunter, and Tales of Zestiria. Additionally, he is the creator of the animated series and video game TOME: Terrain of Magical Expertise.

Niosi made a public statement on social media that addressed rumors about his personal life. In the statement, Niosi emphasizes his dedication to growth, both personally and professionally while giving more insight to events that occurred. Niosi also stated that over the past five years, he has actively worked on self-improvement through therapy, mentorship, and creative collaboration with industry peers.

“I believe in learning and evolving, both as a professional and as a person,” Niosi shared. “I’m grateful for the opportunities to continue contributing to projects I’m passionate about and for the support of colleagues and fans along the way.”

Industry professionals who have worked closely with Niosi acknowledge his dedication to his craft and his ongoing commitment to growth.

Lauren Flagg, a longtime collaborator, stated:

“Chris has consistently shown his passion for animation and voice acting. His dedication to his work and personal development is evident in everything he does.”

Looking ahead, Niosi remains focused on his upcoming projects in animation and gaming, working alongside talented creators in the industry. His dedication to storytelling and character performance continues to shape his career as he takes on new creative challenges.

For updates on his latest work, follow Chris Niosi on his official channels.

Contact:

Name – Mattew Smith

Website – www.conreviews.com

Email – press@conreviews.com

Media Contact
Company Name: ConReviews, LLC
Contact Person: Matthew Smith
Email: Send Email
Country: United States
Website: https://www.conreviews.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chris “Kirbopher” Niosi Focuses on Growth and Future Projects in Animation and Voice Acting

Oral Proteins and Peptides Market to Hit USD 20.36 Billion by 2029 with 22.5% CAGR

“Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada)”
Browse 410 market data Tables and 52 Figures spread through 322 Pages and in-depth TOC on “Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) – Global Forecast to 2029

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with a compound annual growth rate (CAGR) of 22.5% from 2024 to 2029. Robust clinical trial pipeline for oral proteins and peptides drugs and increasing investment and funding for research and development and awareness and adoption of oral proteins and peptides among pharmaceutical and biotechnology companies for research. On the other hand, contraindication of oral proteins and peptides and availability of alternative therapies are hampering the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194705708

Browse in-depth TOC on “Oral Proteins and Peptides Market“

407 – Tables

53 – Figures

318 – Pages

Based on molecule, the oral proteins and peptides market is segmented into trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin and others. The semaglutide segment accounted for the largest share of the oral proteins and peptides market. This can be owing to increasing prevalence of diabetes and rising research and development activities for semaglutide indicated for other clinical application.

Among drug class segment, the oral proteins and peptides market is segmented into Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others. The Glucagon Like Peptide-1 (GLP-1) Receptor Agonist segment accounted for the largest share of the oral proteins and peptides market. The large share of this segment can be owing to the increasing approval and robust pipeline of GLP-1 receptor agonist product for various therapeutic condition such as diabetes, obesity and overweight.

Among therapeutic area segment, the oral proteins and peptides market is segmented into genetic disorder, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight and other therapeutic area. The diabetes segment accounted for the largest share of the oral proteins and peptides market. The large share of this segment can be owing to the increasing approvals of oral proteins and peptides for diabetes and robust clinical trial pipeline of drug for diabetes indication.

Among end user segment, the oral proteins and peptides market is segmented into home-care settings, long-term care facilities, hospitals and specialty clinics. In 2023, home-care settings segment accounted for the largest share of the oral proteins and peptides market due to their greater convenience compared to traditional injectable forms, making them more suitable for at-home administration. Furthermore, patients prefer oral medications due to their ease of use and reduced discomfort, which improves adherence to treatment plans.

Based on region, The oral proteins and peptides market is segmented by region into six key areas: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America led the market, followed by Europe in second place and the Asia Pacific in third. North America is expected to experience the highest growth rate during the forecast period. Factors driving this regional growth include the expansion of pharmaceutical R&D activities, rising demand for novel oral proteins and peptides, substantial investments by biopharmaceutical companies and contract manufacturing organizations (CMOs), and ongoing government support for research initiatives.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=194705708

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), and Pfizer Inc. (US) holding the significant global market share and the global Oral proteins and peptides market is highly consolidated.

Novo Nordisk A/S (Denmark):

Novo Nordisk A/S is headquartered in Denmark and currently operates as a leading pharmaceutical company around the world, especially in antidiabetic medications. Due to its wide portfolio of products, vast geographic presence, and well-known global brand, the company has been able to establish itself as a leader in the market. The focused research and manufacturing capabilities of the company about insulins and GLP-1 products, of which RYBELSUS is one, have also significantly contributed toward the success of the company. The company increased its share in the global market for GLP-1 therapies to 55.3% over the period through the first quarter of 2024, significantly higher from 50.8% in 2021. The companies R&D expenditure at US$4.7 billion last year had given great strength to this position, mainly due to its movement into oral versions of the existing drugs like semaglutide that have huge scope and applications.

AbbVie Inc. (US):

AbbVie Inc stands at the number two spot for a US pharmaceutical company focused on oral proteins and peptides. The company oral peptides like linaclotide, along with AbbVie has seen intense focus on other oral peptide products atogepant and Ubrogepant, where it stands ostensibly to take a chunk of the market. The company’s strategic emphasis on gastrointestinal diseases, AbbVie has partly managed to stay ahead in the market through linaclotide. Furthermore, AbbVie has been proactive in forming strategic partnerships and collaborations to advance its product portfolio of oral proteins and peptides. These partnerships with biotech firms, academic institutions, and contract research organizations (CROs) help the company access cutting-edge technologies and novel delivery methods, expanding its footprint in the market.

Pfizer Inc. (US):

Pfizer Inc. is one of the US-based global health giants, entering the oral peptide market through NURTEC ODT – a CGRP receptor antagonist used for the treatment of episodic migraines. Pfizer’s pipeline seems very strong; one of the drugs in its pipeline is Danuglipron, which is an oral GLP-1 receptor agonist in phase II clinical development. Pfizer has also focused on business acquisitions to focus on. For example, NURTEC ODT became part of Pfizer portfolio through the acquisition of Bio haven Pharmaceutical in October 2022.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/oral-proteins-peptides-market-194705708.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oral Proteins and Peptides Market to Hit USD 20.36 Billion by 2029 with 22.5% CAGR

Tatiana Blanque Presents ‘Interferences’ at Art Madrid during ARCO Week 2025

Barcelona-based artist Tatiana Blanque will participate in the next editionof Art Madrid to be held March 5-9, 2025 at the Galeria de Cristal del Palacio de Cibeles. Her presence at the fair coincides with the prestigious ARCO Week, consolidating her role as one of the highlighted voices at the Spanish contemporary art fair.

On this occasion, Blanque will present her new series of works, ‘Interferences’, a proposal that delves into the relationship between human beings and their natural environment, a recurring theme in her career. The artist, known for her exploration of the landscape and the memory of ecosystems, uses in this series the superimposition of elements, textures and transparencies to represent the constant dialogue between the natural and the artificial, the ephemeral and the permanent. ‘Interferences’ is a reflection of how human activity alters the balance of nature, generating frictions and new visual realities that invite reflection.

This new line of works has been overseen by Odile Art Advisor, an independent agent specializing in the promotion and curatorship of contemporary art. “Tatiana Blanque’s work invites us to rethink our relationship with the landscape and the imprint we leave on it. ‘Interferences’ is a” metaphor for the struggle between the noise of modernity and the harmony of nature,” highlights Odile Art Advisor.

International expansion and consolidation in Spain

Blanque’s participation in Art Madrid is part of a period of consolidation and growth of her work, both nationally and internationally. In Spain, her collaboration with the Galeria Espiral from Cantabria has been important to position her in the market, allowing Tatiana to connect with collectors and art lovers who value her sensitivity towards the landscape and her discourse on sustainability.

Internationally, 2024 marked a milestone in Tatiana Blanque’s career with her first foray into Miami, a key city in the global contemporary art circuit. Her work was well received in this demanding market, which has allowed her to expand her presence in the United States with new collaborations in 2025. Her evolution in this context reflects the universal character of her work and her ability to dialogue with different cultures and sensibilities.

An art committed to nature

Tatiana Blanque’s work is distinguished by her deep commitment to nature and her ability to convey, through textures and organic forms, the fragility and resilience of ecosystems. ‘Interferences’ is not only a continuation of this research, but also a step forward in her experimentation with materials and techniques that allow her to create enveloping and meaningful atmospheres.

Blanque’s presence at Art Madrid 2025 confirms her position as one of the most relevant artists in the Spanish contemporary art scene, while reinforcing her international projection.

Instagram: https://www.instagram.com/tatianablanque/

For more information, interviews or images of the work, please contact below.

Media Contact
Contact Person: Tatiana Blanque
Email: Send Email
Country: Spain
Website: http://www.tatianablanque.com/

MWC 2025: FOSSiBOT Introduces 7200W Solar Generator and Starlight Night Vision Camera Rugged Phone

Barcelona, Spain – March 4th, 2025 – FOSSiBOT, a new rising star brand from China showcases new feature rugged smartphones, rugged tablets, balcony portable power station, and highest outlet power 7200W home energy solar generator at MWC2025 with booth No.:7D9, Hall 3. As one of the world’s most influential communications and technology events, MWC 2025 brings together top companies and industry leaders from around the world. So what FOSSiBOT brought to this exhibition to show their latest breakthroughs and future vision in the field of intelligent technology?

MWC2025: New concept environment-friendly rugged phone FOSSiBOT F112 Pro

FOSSiBOT F112 Pro: this rugged phone is the industry-first smartphone to adopt liquid silicone gel material which is environmentally friendly. Due to the material, the F112 Pro is skin-friendly soft, colorful, IP68-waterproof, shock-resistance, dustproof and thinner than other clumsy rugged phones. The F112 Pro is generally a mid-ranger with 8GB RAM+256GB ROM, 50MP+5MP macro cameras, and Dimensity 6300 5G processor. The F112 Pro will be launched soon by middle March, 2025.

MWC2025: Global first starlight night vision camera rugged phone FOSSiBOT F107 Pro

FOSSiBOT F107 Pro: for the first time, FOSSiBOT combines starlight night vision camera with smartphones. The starlight night vision camera is mostly used in car’s reversing imaging or full color supervisory control cameras, but now, it’s on the F107 Pro. The starlight night vision camera generates full color images with slight star light, the darker the environment is, the better photo effect it will take. In one word: you can take a full color photo like daylight in super dark environment. Besides the starlight night vision camera, the F107 Pro will come with a 28000mAh huge battery and a strong lumen flashlight torch. The F107 Pro is expected to go to market by May 2025. At FOSSiBOT booth 7D9, many visitors are eager to experience the F107 Pro’s starlight night vision camera.

MWC 2025: The highest output power 7200W power station F7200.

FOSSiBOT F7200: as the name it suggests, the F7200 offers 7200W constant AC output power which is the highest in the market. It will come with 5.22kwh capacity power with EV-grade lifepo4 battery. By AC+solar panels charge simultaneously, the 5.22kwh power will be fully recharged in just 1.5 hours. With such huge capacity and high output power, the F7200 is suitable for off-grid living, home backup power and RV living. This will be a new energy product that maximizes the use of solar energy

MWC2025: New balcony power station FBP1200

FOSSiBOT FBP1200: it offers a whole system of generating solar power by solar panels>store electricity>using electricity in household. The FBP1200 offers 800W max AC output power to household appliances intelligently with wall socket connected, saving energy bills and contribute to environment with sustainable green energy. If you are willing to go outside for camping, the FBP1200 offers 1200W max AC output power.

Besides the above 4 products, FOSSiBOT also brings their hot sellers rugged phones like F109, F106 Pro, and hot sellers power stations like FOSSiBOT F2400, FOSSiBOT F1200 and FOSSiBOT F3600 Pro. Fossibot has always been committed to combining technological innovation with sustainable development. We believe that the future of technology is not only about innovation, but also about responsibility. Fossibot will continue to promote the development of green technology and provide users around the world with more environmentally friendly and sustainable smart products.

For more products, keep an eye on FOSSiBOT social media or visit booth 7D9, hall 3 at Barcelona MWC2025.

Media Contact
Company Name: FOSSiBOT
Contact Person: Joanna Chen
Email: Send Email
Country: China
Website: www.fossibot.com

Austin Technology Celebrates Honors For Perth’s Best IT Company Award 2025

Austin Technology Celebrates Honors For Perth’s Best IT Company Award 2025
MSP Pie is a prestigious organization committed to acknowledging excellence in the IT services sector. Each year, they bestow awards upon companies that demonstrate exceptional innovation, quality, and sustainable practices. By doing so, MSP Pie establishes a benchmark for success and ongoing development within the industry.

Perth, Australia – March 4, 2025 – Austin Technology is Perth’s dependable IT company, armed with a team of seasoned experts and a dedication to swift action. Their services extend beyond simple troubleshooting; they take a proactive approach to managing clients’ IT systems. In the event of any issues, they conduct thorough investigations to pinpoint the cause and prevent future occurrences.

Austin Technology has established itself as a powerhouse in the highly competitive IT scene of Perth. Through their unwavering dedication to providing comprehensive and innovative solutions that cater to various business demands, they have solidified their position as leaders in the industry. Perth’s Best IT Company Award 2025 was bestowed upon them following a rigorous evaluation, which emphasized their expertise in driving digital progress and empowering enterprises through the utilization of advanced technology.

Austin Technology’s Core Values and Distinctive Strengths:

  • Innovative IT Solutions: The company is renowned for creating custom strategies that address complex IT challenges while propelling businesses towards digital excellence.
  • Customer-Centric Approach: Austin Technology places a high premium on customer satisfaction, ensuring that every client receives personalized service and proactive support.
  • Expert Team and Visionary Leadership: With a team of highly skilled professionals and forward-thinking leaders, Austin Technology is committed to delivering excellence in every project.
  • Sustainable IT Practices: Their approach integrates best practices that not only enhance business performance but also promote long-term sustainability and reliability.

During a recent interview, Alex Thompson, CEO of Austin Technology, made these comments, “Being recognized as Perth’s Best IT Company is a reflection of our team’s dedication and the trust our clients have placed in us.” He went on to say, “Our mission has always been to empower businesses with innovative IT solutions that are both robust and adaptive. This award inspires us to continue pushing the boundaries of what’s possible in technology, ensuring our clients stay ahead in an ever-evolving digital world.”

The Austin Technology difference:

  • Local IT Team: With a team based right here in Perth, they understand our business landscape, and we’re deeply embedded into the local community.
  • Rapid Response Times: Their service desk is renowned for its speed—tickets are triaged and addressed within 15 minutes. This means minimal downtime for businesses, fast solutions to IT issues, and speedy assistance for employees.
  • ACSC Essential 8 Expertise: They prioritize protecting businesses from cyber threats. Their wide range of cyber security services are aligned with the Australian Cyber Security Centre (ACSC) Essential 8 risk mitigation controls to protect clients’ data and IT infrastructure.
  • Proven Track Record: Supporting over 3000 end-users across industries like medical, engineering, nonprofits, and more, they have the experience to handle IT environments of any scale, no matter the tech complexities clients are up against.
  • Customized Solutions: They don’t believe in a one-size-fits-all plan. Their IT services are tailored to meet the specific needs of one’s business, so they get the right support.
  • Certified Microsoft Partner: As a Microsoft Solutions Partner, they have the expertise to manage clients’ Microsoft environment, from integrations and subscription management to advanced support for apps like OneDrive, SharePoint, and Power BI.
  • Technical Knowledge: Their team of experts is fully certified and qualified in various areas of IT. They constantly train to ensure businesses receive the highest security and best IT practices.
  • Future-Proof Your Business: The threat of cyberattacks is real and increasing. It’s vital for businesses to partner with an IT company that understands these threats and is proactive about preventing an attack from occurring.
  • 24/7 Unlimited IT Support: Should clients experience an IT issue, it’s good to know they always have a team of experts on call. No waiting and minimal downtime.

With Austin’s backing, you’ll tap into operational efficiencies that can grow alongside your business, providing a competitive advantage and maximizing the value of your technology investments. Count on them to keep your business ahead by offering solutions specifically crafted to propel growth and bolster resilience.

For complete information, visit: https://austintechnology.com.au/

Media Contact
Company Name: Austin Technology
Contact Person: Media Relations
Email: Send Email
Phone: 1300 787 429
Address:Level 2, 541 Hay St
City: Subiaco
State: WA 6008
Country: Australia
Website: austintechnology.com.au/

SafeTest Solutions 24/7 Drug Testing 24/7 Expands Reliable Drug and DNA Testing Services in Philadelphia

SafeTest Solutions 24/7 Drug Testing 24/7 Expands Reliable Drug and DNA Testing Services in Philadelphia
SafeTest Solutions 24/7 Drug Testing is strengthening its commitment to accurate and confidential testing services by expanding its offerings in Philadelphia. The company provides around-the-clock access to drug and DNA testing, ensuring individuals, businesses, and legal professionals have reliable results whenever needed.

With a growing demand for DNA Testing Philadelphia, SafeTest Solutions 24/7 Drug Testing offers legally admissible and private testing for various purposes. Whether for establishing paternity, verifying biological relationships, or fulfilling legal requirements, the company provides precise and timely results. Each test is conducted in accredited laboratories to ensure the highest standards of accuracy. Services are available for personal, legal, and corporate needs.

SafeTest Solutions 24/7 Drug Testing also specializes in Drug Testing Philadelphia, catering to employers, court-ordered cases, and personal testing needs. The company provides a full range of testing options, including urine, hair follicle, and saliva drug screenings. By offering 24/7 availability, SafeTest Solutions 24/7 Drug Testing ensures individuals and businesses can access reliable testing without delays, supporting workplace safety and legal compliance. Mobile testing options are also available for added convenience.

Additionally, the company assists individuals navigating the immigration process with an Immigration DNA Test in Philadelphia. Many immigration applications require DNA verification to prove familial relationships, and SafeTest Solutions 24/7 Drug Testing streamlines the process with fast, government-approved testing. Experienced professionals handle each case with discretion, ensuring compliance with immigration guidelines while delivering prompt and accurate results. Testing is conducted in certified laboratories, meeting strict federal and international requirements.

SafeTest Solutions 24/7 Drug Testing remains dedicated to providing trusted and accessible testing solutions in Philadelphia. By maintaining strict confidentiality, accuracy, and 24/7 availability, the company continues to be a dependable resource for legal, personal, and workplace testing needs.

For more information or to schedule a test, visit https://www.safetestsolutions.com/ or contact SafeTest Solutions 24/7 Drug Testing at (484) 324-6984.

Media Contact
Company Name: SafeTest Solutions 24/7 Drug Testing
Contact Person: Shackeal Johnson
Email: Send Email
Phone: (484) 324-6984
Address:8400 Bustleton Ave Suite 309
City: Philadelphia
State: PA
Country: United States
Website: https://www.safetestsolutions.com/bustleton

Brian Arteaga Expands Real Estate Holdings and Launches Legal Tech Platform

Investor and entrepreneur Brian Arteaga is making strides in real estate and legal technology with bold expansion moves and innovative solutions. His real estate portfolio spans multi-family and single-family properties across Nevada, Georgia, and Ohio, with planned expansions into Texas and Florida, along with global ventures in Mexico. He is also expanding his hospitality investments with hotel partnerships in Thailand and Mexico, while actively pursuing developments in Batumi, Bali, and Dubai.

As he nears completion of his Juris Doctor (JD) degree, Arteaga is leveraging his legal expertise to address a critical gap in legal services. He founded Legal Match Experts and launched LegallyBrilliant.com, a platform designed to connect individuals with specialized attorneys quickly and efficiently. Many clients struggle to find the right legal representation, often hiring lawyers outside their area of expertise or facing language barriers.

LegallyBrilliant.com simplifies the process by providing free matches with up to three vetted attorneys, ensuring users consult the right experts before making a decision. The platform also offers translation services to bridge language gaps, making legal representation more accessible.

“Too often, people waste time and money on lawyers who aren’t the right fit for their needs,” said Arteaga. “LegallyBrilliant.com changes that by offering a fast, free, and reliable way to connect with specialized attorneys across various fields, from real estate and bankruptcy to personal injury and family law.”

With nationwide coverage and next-day matching, LegallyBrilliant.com is set to transform legal access. The process takes just minutes, saving users time, money, and frustration.

As Arteaga continues expanding his global real estate footprint and disrupting the legal industry, his focus remains on accessibility, efficiency, and innovation.

For more information, visit LegallyBrilliant.com.

About Brian Arteaga

Brian Arteaga is a Beverly Hills, California-based real estate investor, hotel developer, and legal entrepreneur. His real estate portfolio includes properties across the U.S. and Mexico, alongside international hotel partnerships in Thailand and Mexico, with future developments in Georgia, Indonesia, and U.A.E. As the founder of Legal Match Experts and LegallyBrilliant.com, he is revolutionizing how consumers find legal representation. Arteaga is currently completing his Juris Doctor (JD) degree and preparing for the California Bar Exam.

Media Contact
Company Name: LegallyBrilliant.com
Contact Person: Brian Arteaga
Email: Send Email
City: Beverly Hills
State: CA
Country: United States
Website: LegallyBrilliant.com